36P Unveiling the toxicity landscape: Insights from 112 patients treated with chromatin remodeler agents in a phase I unit
Chromatin remodeler agents, including BET, HDAC6, PRMT5, LSD1 and EZH2 inhibitors, are emerging therapies that modulate epigenetic regulation and hold potential in treating solid and hematological malignancies. While promising, these agents necessitate evaluation of their toxicity profiles, particularly in heavily pretreated populations. This study aims to characterize the adverse event (AE) profiles associated with these agents in a phase I oncology unit.
Authors
- Teresa Cenarro Guerrero (ORCID: https://orcid.org/0000-0003-3934-6722)
- Víctor Moreno (ORCID: https://orcid.org/0000-0001-6099-4236)
- B. Doger de Spéville
- Natalia García (ORCID: https://orcid.org/0000-0003-3204-561X)
- Mercedes Ruidíaz (ORCID: https://orcid.org/0000-0002-8153-1473)
- Milton Trujillo
- Elena Lorenzo
- C. Lacalle
Institutions
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Delfos Hospital (ES)
- Spanish Head & Neck Cancer Cooperative Group (ES)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104194
- Primary Topic
- Chromatin Remodeling and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00